ClinicalTrials.gg
CompletedNCT03759392METEORIC-HFUpdated Mar 7, 2023Results posted

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

A Phase 3 interventional study of Omecamtiv Mecarbil and Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Cytokinetics. Completed at 81 sites in 9 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-03-07.

Sponsored by Cytokinetics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
4th of 14
276 · median 48
Started
2019
the only one that year
Phase 3
4 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 12th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo

Read the detailed description

Oversight Authorities:

United States: Food and Drug Administration Canada: Health Canada France: National Agency for the Safety of Medicine and Health Products Germany: Federal Institute for Drugs and Medical Devices Hungary: National Institute of Pharmacy and Nutrition Italy: Italian Medicines Agency Netherlands: Medicines Evaluation Board Poland: Chief Pharmaceutical Inspectorate Sweden: Medical Products Agency

03

Conditions studied

  • Heart Failure With Reduced Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, greater than or equal to 18 to lesser than or equal to 85 years of age
  • History of chronic HF, defined as requiring continuous treatment with medications for HF for a minimum of 3 months before screening
  • (NYHA) class II or III at screening
  • less than or equal to 35%
  • On maximally tolerated HF standard of care (SoC) therapies consistent with regional clinical practice guidelines, if not and according to investigator judgment of the subject's clinical status. Beta blocker dose must be stable for 30 days prior to randomization.
  • N-terminal (NT)-proBNP level greater than or equal to 200 pg/mL
  • Peak VO2 less than or equal to 75% of the predicted normal value with respiratory exchange ratio (RER) greater than or equal to 1.05 on a screening CPET, confirmed by a CPET core laboratory

Exclusion criteria

Exclusion Criteria

  • Severe uncorrected valvular heart disease
  • Paroxysmal atrial fibrillation or flutter documented within the previous 6 months, direct-current (DC) cardioversion or ablation procedure for atrial fibrillation within 6 months, or plan to attempt to restore sinus rhythm within 6 months of randomization. Subjects with persistent atrial fibrillation and no sinus rhythm documented in the prior 6 months are permitted.
  • Symptomatic bradycardia, second-degree Mobitz type II, or third-degree heart block without a pacemaker.
  • History of gastrointestinal bleeding requiring hospitalization, urgent procedure or transfusion in the prior year, or received intravenous (IV) iron, blood transfusion, or an erythropoiesis-stimulating agent (ESA) within 3 months prior to screening, or planned blood transfusion or ESA use during the study screening or treatment period. Chronic, stable use of oral iron is permitted.
  • Ongoing or planned enrollment in cardiac rehabilitation.
  • Requires assistance to walk or use of mobility assistive devices such as motorized devices, wheelchairs, or walkers. The use of canes for stability while ambulating is acceptable if the subject is deemed capable of performing CPET.
  • Major medical event or procedure within 3 months prior to randomization, including: hospitalization, surgery, renal replacement therapy or cardiac procedure. This includes episodes of decompensated HF that require IV HF treatment.
  • At screening: Resting systolic BP greater than 140 mmHg or less than 85 mmHg, or diastolic BP greater than 90 mmHg (mean of triplicate readings); Resting heart rate greater than 90 beats per minute, or less than 50 beats per minute (mean of triplicate readings); Estimated (eGFR) less than 30 mL/min/1.73m2 (by the modified Modification of Diet in Renal Disease equation); Hepatic impairment defined by a total (TBL) greater than or equal to 2 times the (ULN), or (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times ULN. Patients with documented Gilbert syndrome and TBL greater than or equal to 2 times ULN due to unconjugated hyperbilirubinemia, without other hepatic impairment, are permitted.
  • Room air oxygen saturation under 90% at screening
  • less than 10.0 g/dL at screening
  • Significant adverse finding (e.g., exercise-induced early ischemic changes, abnormal decrease in BP [systolic BP falls by more than 10 mmHg], unexpected arrhythmia or other serious finding) during CPET at screening that precludes safe participation in the study, per investigator
  • Chronotropic incompetence (including inadequate pacemaker rate response) during CPET at screening, defined as a maximum heart rate \<60% of the maximum predicted heart rate
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Omecamtiv Mecarbil

    Omecamtiv mecarbil was administered as an oral modified-release tablet twice daily for up to 20 weeks. Participants randomized to this arm started at an omecamtiv mecarbil dose of 25 mg twice daily. The dose could be increased based on plasma concentrations at Weeks 2 and 6.

    Drug: Omecamtiv Mecarbil

  • Placebo comparator
    Placebo

    Participants randomized this arm received placebo tablets (matching the appearance of the omecamtiv mecarbil tablets) twice daily for up to 20 weeks.

    Drug: Placebo

Interventions

  • Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing

    Also known as: CK-1827452, AMG-423

  • DrugPlacebo

    Oral placebo twice daily for up to 20 weeks

06

What researchers measure

Primary outcomes

  1. Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20

    The effect of treatment on exercise capacity, as assessed by peak oxygen uptake, was assessed during cardiopulmonary exercise testing (CPET) with gas-exchange analysis. Cycle ergometry was the preferred modality for exercise testing; treadmill exercise testing was an acceptable alternative. Participants were to use the same testing modality for all exercise tests during the study. Whenever possible, CPET was administered by the same study personnel using the same equipment throughout the study.

    Time frame: Baseline and Week 20

Secondary outcomes

  1. Change in Total Workload During Cardiopulmonary Exercise Testing From Baseline to Week 20

    Total workload was measured during CPET (cycle ergometry \[preferred\] or treadmill exercise testing) and represents the maximum load to which a participant was subjected during CPET in order to produce work.

    Time frame: Baseline and Week 20

  2. Change in Ventilatory Efficiency During Cardiopulmonary Exercise Testing From Baseline to Week 20

    Ventilatory efficiency (ventilation \[VE\]/volume of exhaled carbon dioxide \[VCO2\]) was measured through CPET with gas exchange analysis.

    Time frame: Baseline and Week 20

  3. Change in the Average Daily Activity Units Measured Over a 2-week Period From Baseline (Week -2 to Day 1) to Weeks 18-20

    The effect of treatment on daily activity, as assessed by average daily activity units, was evaluated by actigraphy. Actigraphy was collected during 4 sessions throughout the study for 2 week intervals.

    Time frame: Baseline (Week -2 to Day 1) to Weeks 18-20

07

Results

Posted Mar 7, 2023

Participant flow

Participants with heart failure with reduced ejection fraction (HFrEF) were enrolled at 63 sites in Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Sweden, and the United States. The first participant enrolled on 09 April 2019, and the last participant completed follow-up on 06 January 2022.

Participant flow — Overall Study
MilestoneOmecamtiv MecarbilPlacebo
Started18591
Completed16485
Not completed216
Withdrew: Adverse event124
Withdrew: Death21
Withdrew: Withdrawal by subject20
Withdrew: Protocol violation20
Withdrew: Physician decision01
Withdrew: Consistently forgot to bring study drug kits to site visits (for compliance check)10
Withdrew: No longer able to take medicines10
Withdrew: Stopped taking study drug10

Outcome measures

PrimaryChange in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20

The effect of treatment on exercise capacity, as assessed by peak oxygen uptake, was assessed during cardiopulmonary exercise testing (CPET) with gas-exchange analysis. Cycle ergometry was the preferred modality for exercise testing; treadmill exercise testing was an acceptable alternative. Participants were to use the same testing modality for all exercise tests during the study. Whenever possible, CPET was administered by the same study personnel using the same equipment throughout the study.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mL/min/kg
Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20
mL/min/kgOmecamtiv MecarbilPlacebo
Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20-0.239 ± 0.17180.207 ± 0.2412
Statistical analysis
  • Omecamtiv Mecarbil vs Placebo · ANCOVA · p = 0.13 · Least squares mean difference: -0.447 · 95% CI -1.024 to 0.131Using multiple imputation
SecondaryChange in Total Workload During Cardiopulmonary Exercise Testing From Baseline to Week 20

Total workload was measured during CPET (cycle ergometry \[preferred\] or treadmill exercise testing) and represents the maximum load to which a participant was subjected during CPET in order to produce work.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · Watt
Change in Total Workload During Cardiopulmonary Exercise Testing From Baseline to Week 20
WattOmecamtiv MecarbilPlacebo
Change in Total Workload During Cardiopulmonary Exercise Testing From Baseline to Week 20-3.798 ± 1.33521.590 ± 1.9477
Statistical analysis
  • Omecamtiv Mecarbil vs Placebo · ANCOVA · p = 0.025 · Least squares mean difference: -5.388 · 95% CI -10.108 to -0.0668Using multiple imputation
SecondaryChange in Ventilatory Efficiency During Cardiopulmonary Exercise Testing From Baseline to Week 20

Ventilatory efficiency (ventilation \[VE\]/volume of exhaled carbon dioxide \[VCO2\]) was measured through CPET with gas exchange analysis.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · slope
Change in Ventilatory Efficiency During Cardiopulmonary Exercise Testing From Baseline to Week 20
slopeOmecamtiv MecarbilPlacebo
Change in Ventilatory Efficiency During Cardiopulmonary Exercise Testing From Baseline to Week 200.277 ± 0.3616-0.138 ± 0.5065
Statistical analysis
  • Omecamtiv Mecarbil vs Placebo · ANCOVA · p = 0.51 · Least squares mean difference: 0.414 · 95% CI -0.810 to 1.639Using multiple imputation
SecondaryChange in the Average Daily Activity Units Measured Over a 2-week Period From Baseline (Week -2 to Day 1) to Weeks 18-20

The effect of treatment on daily activity, as assessed by average daily activity units, was evaluated by actigraphy. Actigraphy was collected during 4 sessions throughout the study for 2 week intervals.

Time frame:
Baseline (Week -2 to Day 1) to Weeks 18-20
Reported as:
Least squares mean · 10^5 activity units
Change in the Average Daily Activity Units Measured Over a 2-week Period From Baseline (Week -2 to Day 1) to Weeks 18-20
10^5 activity unitsOmecamtiv MecarbilPlacebo
Change in the Average Daily Activity Units Measured Over a 2-week Period From Baseline (Week -2 to Day 1) to Weeks 18-20-0.2 ± 0.30-0.5 ± 0.38
Statistical analysis
  • Omecamtiv Mecarbil vs Placebo · Repeated measures mixed model · p = 0.54 · Least squares mean difference: 0.3 · 95% CI -0.6 to 1.1

Adverse events

Collected over Adverse events were collected from randomization through the end of study/safety follow-up visit (scheduled to occur 4 weeks after the last dose of study drug) or 30 days after the last dose of study drug, whichever was later.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Omecamtiv Mecarbil3/185 (1.6%)30/185 (16.2%)126/185 (68.1%)
Placebo1/91 (1.1%)13/91 (14.3%)58/91 (63.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventOmecamtiv MecarbilPlacebo
Cardiac failureCardiac disorders7/1851/91
Cardiac failure acuteCardiac disorders2/1853/91
Ventricular tachycardiaCardiac disorders5/1852/91
Acute myocardial infarctionCardiac disorders0/1852/91
Atrial fibrillationCardiac disorders2/1851/91
Supraventricular tachycardiaCardiac disorders0/1851/91
Abscess limbInfections and infestations0/1851/91
Urinary tract infectionInfections and infestations0/1851/91
Ischaemic strokeNervous system disorders0/1851/91
Gastrointestinal haemorrhageGastrointestinal disorders0/1851/91
Most frequent other events
Showing 10 of 30
Most frequent other events
EventOmecamtiv MecarbilPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1858/91
DizzinessNervous system disorders9/1855/91
FatigueGeneral disorders9/1854/91
Back painMusculoskeletal and connective tissue disorders5/1854/91
DiarrhoeaGastrointestinal disorders7/1854/91
RashSkin and subcutaneous tissue disorders0/1854/91
FallInjury, poisoning and procedural complications7/1851/91
Angina pectorisCardiac disorders4/1853/91
Atrial fibrillationCardiac disorders4/1853/91
Non-cardiac chest painGeneral disorders4/1853/91

Baseline characteristics

Age, Continuous
Age, Continuous(years)Omecamtiv MecarbilPlaceboTotal
Mean63.3 ± 9.6464.4 ± 11.4163.6 ± 10.25
Sex: Female, Male
Sex: Female, Male(Participants)Omecamtiv MecarbilPlaceboTotal
Female271542
Male15876234
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Omecamtiv MecarbilPlaceboTotal
American Indian or Alaska Native101
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American16622
White16382245
More than one race000
Unknown or Not Reported213
Time since HFrEF diagnosis
Time since HFrEF diagnosis(years)Omecamtiv MecarbilPlaceboTotal
Mean7.6 ± 6.147.8 ± 6.887.7 ± 6.38
Primary cause of heart failure: ischemic heart disease
Primary cause of heart failure: ischemic heart disease(Participants)Omecamtiv MecarbilPlaceboTotal
Count of participants11748165
08

Study locations

81 sites
  • Alaska Heart and Vascular Institute
    Anchorage, Alaska 99508, United States
  • Arkansas Cardiology Clinic
    Little Rock, Arkansas 72205, United States
  • Harbor-UCLA Medical Center
    Torrance, California 90509, United States
  • South Denver Cardiology Associates, PC
    Littleton, Colorado 80120, United States
  • Hartford Hospital-University of Connecticut School of Medicine
    Hartford, Connecticut 06102, United States
  • Holy Cross Hospital - Fort Lauderdale
    Fort Lauderdale, Florida 33308-4603, United States
  • Broward Research Center - Pembroke Pines
    Pembroke Pines, Florida 33024, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Community Hospital South, Inc.
    Indianapolis, Indiana 46227, United States
  • Saint Vincent Medical Group Inc.
    Indianapolis, Indiana 46260, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital (MGH) - Cardiac Unit Associates
    Boston, Massachusetts 02114-2621, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Heart & Vascular Institute
    Detroit, Michigan 48202, United States
  • McLaren Health Care Corporation
    Petoskey, Michigan 49770, United States
  • Michigan Heart
    Ypsilanti, Michigan 48197, United States
  • Saint Luke's Health System
    Kansas City, Missouri 64111, United States
  • Glacier View Research Institute, Cardiology
    Kalispell, Montana 59901, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Cardiovascular Associates Of The Delaware Valley (Cadv), P.A. - Elmer Physicians Care Center - Elmer
    Elmer, New Jersey 08318, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Queens Heart Institute
    Rosedale, New York 11422, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Med Health and Hospital
    Raleigh, North Carolina 27610, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27101, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • St. John Clinical Research Institute
    Tulsa, Oklahoma 74104, United States
  • Oregon Health
    Portland, Oregon 97239, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Penn State Hershey Children's Hospital
    Hershey, Pennsylvania 17033, United States
  • Lancaster Heart And Stroke Foundation
    Lancaster, Pennsylvania 17603, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • University of Texas - Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Baylor Scott and White Heart and Vascular Hospital
    Dallas, Texas 75246, United States
  • Inova Heart and Vascular Institute
    Falls Church, Virginia 22042, United States
  • Foothills Medical Centre
    Calgary, Alberta T2N 4Z6, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Universite de Montreal Institut de Cardiologie de Montreal ICM Montreal Heart Institute MHI
    Montreal, Quebec H1Y 3N1, Canada
  • Mcgill University Health Centre (MUHC)-The Montreal General Hospital (MGH)
    Montreal, Quebec H3P1E1, Canada
  • Centre Hospitalier De La Cote Basque
    Bayonne cedex, 64109, France
  • Groupe Hospitalier Mutualiste de Grenoble
    Grenoble, 38028, France
  • Centre Hospitalier Universitaire de Grenoble-Hopital Albert Michallon
    La Tronche, 38700, France
  • Universite De Nantes - L'Institut Du Thorax
    Nantes CEDEX 1, 44093, France
  • Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Lariboisiere
    Paris, 75010, France
  • Chu de Rouen Hopital Charles Nicolle
    Rouen Cedex, 76031, France
  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Rangueil
    Toulouse Cedex 9, 31059, France
  • Universitaetsklinik Heidelberg
    Heidelberg, Baden-wurttemberg 69120, Germany
  • Universitatsklinikum Magdeburg
    Magdeburg, Saxony-Anhalt 39120, Germany
  • Universitaetsklinikum Jena
    Jena, Thueringen 07747, Germany
  • Kerckhoff-Klinik- Bad Nauheim
    Bad Nauheim, 61231, Germany
  • Praxisklinik Dresden
    Dresden, 01099, Germany
  • Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes
    Homburg, 66421, Germany
  • Balatonfuredi Allami Szivkorhaz
    Balatonfured, 8230, Hungary
  • Semmelweis University Heart and Vascular Center
    Budapest, 1122, Hungary
  • Pecsi Tudomanyegyetem (PTE) Altalanos Orvostudomanyi Kar (AOK) (University of Pecs Medical School)
    Pecs, 7624, Hungary
  • Ospedali Riuniti Foggia
    Foggia, Apulia 71100, Italy
  • Centro Cardiologico Monzino IRCCS
    Milano, Lombardia 20138, Italy
  • Azienda Ospedaliera S.Orsola Malpighi
    Bologna, Province Of Bologna 40138, Italy
  • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
    Brescia, Province Of Brescia 25123, Italy
  • Insituto Di Ricovero E Cura A Carattere Scientifico San Raffaele Pisana
    Roma, Rome 00163, Italy
  • Divisione di Cardiologia con Utic ed Emodinamica
    Napoli, 80131, Italy
  • Ospedale Monaldi
    Napoli, 80131, Italy
  • Erasmus MC - Universitair Medisch Centrum Rotterdam
    Rotterdam, South Holland 3000 CA, Netherlands
  • Jeroen Bosch Ziekenhuis
    'S-Hertogenbosch, 5223 GZ, Netherlands
  • Onze Lieve Vrouwe Gasthuis (OLVG) Locatie West
    Amsterdam, 1061 AE, Netherlands
  • University Medical Center Groningen
    Groningen, 9713 GZ, Netherlands
  • Leids Universitair Medisch Centrum (LUMC)
    Leiden, 2300RC, Netherlands
  • Radboud Universiteit - Radboud Universitair Medisch Centrum (Radboudumc)
    Nijmegen, 6500 HB, Netherlands
  • Universitair Medisch Centrum Utrecht - Wilhelmina Kinderziekenhuis
    Utrecht, 3584 CX, Netherlands
  • Maxima Medisch Centrum Veldhoven
    Veldhoven, 5504 DB, Netherlands
  • Centrum Medyczne Medyk Sp z o.o. Sp. k.
    Rzeszow, Podkarpackie 35-055, Poland
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • Uniwersyteckie Centrum Kliniczne Kliniczne Centrum Kardiologii
    Gdansk, 80-952, Poland
  • Oddzial Kliniczny Choroby Wiencowej i Niewydolnosci Serca z Pododdzialem Intensywnego Nadzoru Kardiologicznego
    Krakow, 31- 202, Poland
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Oddzial Kardiologiczny
    Lodz, 93-513, Poland
  • Instytut Kardiologii Heart Failure Clinic
    Warsaw, 04-628, Poland
  • Centrum Chorob Serca, Uniwersytecki Szpital Kllniczny im. Jana Mikulicza Radeckiego we Wrociawiu
    Wroclaw, 50556, Poland
  • Sahlgrenska Universitetssjukhuset
    Göteborg, 413 45, Sweden
  • Enhet Klinisk forskning, hjartmedicin, Skanes Universitet Sjukhus
    Lund, 22242, Sweden
09

References and documents

Publications

  • Lewis GD, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, Bohm M, Teerlink JR, Docherty KF, Lopes RD, Divanji PH, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Felker GM. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. JAMA. 2022 Jul 19;328(3):259-269. doi: 10.1001/jama.2022.11016. PubMed 35852527 ↗
  • Lewis GD, Docherty KF, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, Ponikowski P, Bohm M, Teerlink JR, Heitner SB, Kupfer S, Malik FI, Meng L, Felker GM. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circ Heart Fail. 2022 May;15(5):e008970. doi: 10.1161/CIRCHEARTFAILURE.121.008970. Epub 2022 Mar 3. PubMed 35236099 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Nov 2021, 30 months.

Results were first posted in Mar 2023, 1 year 3 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 30 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2018
First posted
Nov 30, 2018
StartActual
Apr 9, 2019
Primary completionActual
Nov 8, 2021
CompletionActual
Jan 6, 2022
Results first posted
Mar 7, 2023
Last update
Mar 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03759392
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Nov 30, 2018
Start date
Apr 9, 2019
Primary completion
Nov 8, 2021
Completion
Jan 6, 2022
Results posted
Mar 7, 2023
Last update
Mar 7, 2023

Study contacts

Cytokinetics, MD
study director · Cytokinetics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion